MLL translocations, histone modifications and leukaemia stem-cell development

Nature Reviews Cancer

Volumn 7, Issue 11, 2007, Pages 823-833

  Krivtsov, Andrei V ^a   Armstrong, Scott A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA BINDING PROTEIN; HISTONE H3 LYSINE 4; HISTONE LYSINE METHYLTRANSFERASE; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; UNCLASSIFIED DRUG;

CELL MATURATION; CELL NUCLEUS MATRIX; CELL RENEWAL; CELL TRANSFORMATION; CHROMATIN STRUCTURE; GENE CONTROL; GENE EXPRESSION; GENE TRANSLOCATION; HEMATOPOIETIC CELL; HOX GENE; HUMAN; LEUKAEMIA STEM CELL DEVELOPMENT; METHYLATION; MIXED LINEAGE LEUKAEMIA GENE; POLYCOMB GROUP; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; TRITHORAX GROUP;

ADULT; ANIMALS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMATIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEMATOPOIETIC STEM CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; INFANT; LEUKEMIA; METHYLATION; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR STEM CELLS;

EID: 35548934558     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2253     Document Type: Review

References (121)

1. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001).
2. Rice, J. C. & Allis, C. D. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr. Opin. Cell Biol. 13, 263-273 (2001).
3. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269 (2006).
4. Sparmann, A. & van Lohuizen, M. Polycomb silencers control cell fate, development and cancer. Nature Rev. Cancer 6, 846-856 (2006).
5. Ayton, P. M. & Cleary, M. L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707 (2001).
6. Biondi, A., Cimino, G., Pieters, R. & Pui, C. H. Biological and therapeutic aspects of infant leukemia. Blood 96, 24-33 (2000).
7. Huret, J. L., Dessen, P. & Bernheim, A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15, 987-989 (2001).
8. Meyer, C. et al. The MLL recombinome of acute leukemias. Leukemia 20, 777-784 (2006).
9. Chen, C. S. et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81, 2386-2393 (1993).
10. Felix, C. A. et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85, 3250-3256 (1995).
11. Mrozek, K. et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 90, 4532-4538 (1997).
12. Rubnitz, J. E. et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J. Clin. Oncol. 20, 2302-2309 (2002).
13. Gu, Y. et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71, 701-708 (1992).
14. Tkachuk, D. C., Kohler, S. & Cleary, M. L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691-700 (1992).
15. Butler, L. H., Slany, R., Cui, X., Cleary, M. L. & Mason, D. Y. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures. Blood 89, 3361-3370 (1997).
16. Kawagoe, H., Humphries, R. K., Blair, A., Sutherland, H. J. & Hogge, D. E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13, 687-698 (1999).
17. Phillips, R. L. et al. The genetic program of hematopoietic stem cells. Science 288, 1635-1640 (2000).
18. Daser, A. & Rabbitts, T. H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 18, 965-674 (2004).
19. Popovic, R. & Zeleznik-Le, N. J. MLL: how complex does it get? J. Cell Biochem. 95, 234-242 (2005).
20. Ernst, P., Wang, J., Huang, M., Goodman, R. H. & Korsmeyer, S. J. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol. Cell Biol. 21, 2249-2258 (2001).
21. Briggs, S. D. et al. Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae. Genes Dev. 15, 3286-3295 (2001).
22. Milne, T. A. et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 10, 1107-1117 (2002). This paper and reference 28 were the first to demonstrate H3K4 methyltransferase activity of the SET domain in mammalian MLL.
23. Dou, Y. et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nature Struct. Mol. Biol. 13, 713-719 (2006).
24. Steward, M. M. et al. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nature Struct. Mol. Biol. 13, 852-854 (2006).
25. Couture, J. F., Collazo, E. & Trievel, R. C. Molecular recognition of histone H3 by the WD40 protein WDR5. Nature Struct. Mol. Biol. 13, 698-703 (2006).
26. Crawford, B. D. & Hess, J. L. MLL core components give the green light to histone methylation. ACS Chem. Biol. 1, 495-498 (2006).
27. Sims, R. J. III & Reinberg, D. Histone H3 Lys 4 methylation: caught in a bind? Genes Dev. 20, 2779-2786 (2006).
28. Nakamura, T. et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 10, 1119-1128 (2002).
29. Yokoyama, A. et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell Biol. 24, 5639-5649 (2004).
30. Dou, Y. et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873-885 (2005).
31. Zeleznik-Le, N. J., Harden, A. M. & Rowley, J. D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc. Natl Acad. Sci. USA 91, 10610-10614 (1994).
32. Birke, M. et al. The MT domain of the protooncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res. 30, 958-965 (2002).
33. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218 (2005).
34. Xia, Z. B., Anderson, M., Diaz, M. O. & Zeleznik-Le, N. J. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc. Natl Acad. Sci. USA 100, 8342-8347 (2003).
35. Abramovich, C. & Humphries, R. K. Hox regulation of normal and leukemic hematopoietic stem cells. Curr. Opin. Hematol. 12, 210-216 (2005).
36. Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A. & Korsmeyer, S. J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 505-508 (1995).
37. Yagi, H. et al. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 92, 108-117 (1998).
38. Terranova, R., Agherbi, H., Boned, A., Meresse, S. & Djabali, M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc. Natl Acad. Sci. USA 103, 6629-6634 (2006).
39. Hanson, R. D. et al. Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proc. Natl Acad. Sci. USA 96, 14372-14377 (1999).
40. Guenther, M. G. et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc. Natl Acad. Sci. USA 102, 8603-8608 (2005).
41. Hess, J. L., Yu, B. D., Li, B., Hanson, R. & Korsmeyer, S. J. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 90, 1799-1806 (1997).
42. Ernst, P. et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev. Cell 6, 437-443 (2004).
43. Pardal, R., Molofsky, A. V., He, S. & Morrison, S. J. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb. Symp. Quant. Biol. 70, 177-185 (2005).
44. Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260 (2003).
45. Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305 (2003).
46. Milne, T. A. et al. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl Acad. Sci. USA 102, 14765-14770 (2005).
47. Richardson, C. & Jasin, M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 405, 697-700 (2000).
48. Strissel, P. L., Strick, R., Rowley, J. D. & Zeleznik-Le, N. J. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 92, 3793-3803 (1998).
49. So, C. W., Lin, M., Ayton, P. M., Chen, E. H. & Cleary, M. L. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4, 99-110 (2003).
50. So, C. W. & Cleary, M. L. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 101, 633-639 (2003).
51. Hall, P. A. & Russell, S. E. The pathobiology of the septin gene family. J. Pathol. 204, 489-505 (2004).
52. Ida, K. et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 90, 4699-4704 (1997).
53. Taki, T., Sako, M., Tsuchida, M. & Hayashi, Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89, 3945-3950 (1997).
54. Rowley, J. D. et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90, 535-541 (1997).
55. Caligiuri, M. A. et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 56, 1418-1425 (1996).
56. Schichman, S. A. et al. ALL-1 partial duplication in acute leukemia. Proc. Natl Acad. Sci. USA 91, 6236-6239 (1994).
57. Lochner, K. et al. A specific deletion in the breakpoint cluster region of the ALL-1 gene is associated with acute lymphoblastic T-cell leukemias. Cancer Res. 56, 2171-2177 (1996).
58. Slany, R. K., Lavau, C. & Cleary, M. L. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell Biol. 18, 122-129 (1998).
59. Milne, T. A., Martin, M. E., Brock, H. W., Slany, R. K. & Hess, J. L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65, 11367-11374 (2005).
60. Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853-861 (1996). Demonstrates that Mll-AF9 induces leukaemia in mice and describes a method for the generation of 'knock-in' mouse models of translocation-associated human leukaemias.
61. Collins, E. C., Pannell, R., Simpson, E. M., Forster, A. & Rabbitts, T. H. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep. 1, 127-132 (2000).
62. Forster, A. et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3, 449-458 (2003).
63. Wang, J. et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 24, 368-381 (2005).
64. Chen, W. et al. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108, 669-677 (2006).
65. Metzler, M. et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 25, 3093-3103 (2006).
66. Lavau, C., Szilvassy, S. J., Slany, R. & Cleary, M. L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 16, 4226-4237 (1997).
67. So, C. W. et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3, 161-171 (2003).
68. Zeisig, B. B., Garcia-Cuellar, M. P., Winkler, T. H. & Slany, R. K. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 22, 1629-1637 (2003).
69. Barabe, F., Kennedy, J. A., Hope, K. J. & Dick, J. E. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600-604 (2007).
70. Yu, M. et al. MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia 10, 774-780 (1996).
71. Caligiuri, M. A. et al. The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc. Natl Acad. Sci. USA 94, 3899-3902 (1997).
72. Dorrance, A. M. et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Invest. 116, 2707-2716 (2006).
73. Dobson, C. L., Warren, A. J., Pannell, R., Forster, A. & Rabbitts, T. H. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J. 19, 843-851 (2000).
74. Bernard, O. A., Mauchauffe, M., Mecucci, C., Van den Berghe, H. & Berger, R. A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL. Oncogene 9, 1039-1045 (1994).
75. Megonigal, M. D. et al. Detection of leukemiaassociated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl Acad. Sci. USA 97, 2814-2819 (2000).
76. Slany, R. K. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 23, 1-9 (2005).
77. Shilatifard, A., Lane, W. S., Jackson, K. W., Conaway, R. C. & Conaway, J. W. An RNA polymerase II elongation factor encoded by the human ELL gene. Science 271, 1873-1876 (1996).
78. Simone, F. et al. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood 98, 201-209 (2001).
79. Garcia-Cuellar, M. P. et al. ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+. Oncogene 19, 1744-1751 (2000).
80. Prasad, R. et al. Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia. Proc. Natl Acad. Sci. USA 92, 12160-12164 (1995).
81. So, C. W. & Cleary, M. L. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol. Cell Biol. 22, 6542-6552 (2002).
82. Erfurth, F., Hemenway, C. S., de Erkenez, A. C. & Domer, P. H. MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 18, 92-102 (2004).
83. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005). Identifies a unique function of an MLL fusion (MLL-AF10). The recruitment of the H3K79 methyltransferase DOT1L by AF10 is necessary for transformation.
84. Guenther, M. G., Levine, S. S., Boyer, L. A., Jaenisch, R. & Young, R. A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130, 77-88 (2007) .
85. Lachner, M., O'Sullivan, R. J. & Jenuwein, T. An epigenetic road map for histone lysine methylation. J. Cell Sci. 116, 2117-2124 (2003).
86. Zhang, W., Xia, X., Reisenauer, M. R., Hemenway, C. S. & Kone, B. C. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaC? in an aldosterone-sensitive manner. J. Biol. Chem. 281, 18059-18068 (2006).
87. Bitoun, E., Oliver, P. L. & Davies, K. E. The mixedlineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 16, 92-106 (2007).
88. Zeisig, D. T. et al. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24, 5525-5532 (2005).
89. So, C. W. et al. The interaction between EEN and Abi-1, two MLL fusion partners, and synaptojanin and dynamin: implications for leukaemogenesis. Leukemia 14, 594-601 (2000).
90. Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029-3035 (2003). Demonstrates direct transformation of committed myeloid progenitors by an MLL fusion. This finding suggests that cells incapable of self renewal can be transformed by certain oncogenes.
91. Na Nakorn, T., Traver, D., Weissman, I. L. & Akashi, K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU.-S. J. Clin. Invest. 109, 1579-1585 (2002) .
92. Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596 (2004).
93. Miller, C. T., Maves, L. & Kimmel, C. B. moz regulates Hox expression and pharyngeal segmental identity in zebrafish. Development 131, 2443-2461 (2004).
94. Deguchi, K. et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3, 259-271 (2003).
95. Dick, J. E. & Lapidot, T. Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol. 82, 389-396 (2005).
96. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
97. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997).
98. Passegue, E., Wagers, A. J., Giuriato, S., Anderson, W. C. & Weissman, I. L. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599-1611 (2005).
99. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLLAF9. Nature 442, 818-822 (2006).
100. Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006).
101. Kroon, E. et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17, 3714-3725 (1998).
102. Griffin, J. D. & Lowenberg, B. Clonogenic cells in acute myeloblastic leukemia. Blood 68, 1185-1195 (1986).
103. Opferman, J. T. et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101-1104 (2005).
104. Terskikh, A. V., Miyamoto, T., Chang, C., Diatchenko, L. & Weissman, I. L. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 102, 94-101 (2003).
105. Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002).
106. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006).
107. Krause, D. S., Lazarides, K., von Andrian, U. H. & Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nature Med. 12, 1175-1180 (2006).
108. Deshpande, A. J. et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10, 363-374 (2006).
109. Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Med. 12, 1167-1174 (2006).
110. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). A landmark paper demonstrating the ability to induce cellular reprogramming from fibroblasts to ES cells with a limited number of genes.
111. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317 (2007).
112. Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318-324 (2007).
113. Ducasse, M. & Brown, M. A. Epigenetic aberrations and cancer. Mol. Cancer 5, 60 (2006).
114. Feinberg, A. P. Phenotypic plasticity and the epigenetics of human disease. Nature 447, 433-440 (2007).
115. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Rev. Genet. 8, 286-298 (2007).
116. Francis, N. J., Kingston, R. E. & Woodcock, C. L. Chromatin compaction by a polycomb group protein complex. Science 306, 1574-1577 (2004).
117. Papp, B. & Muller, J. Histone trimethylation and the maintenance of transcriptional ON and OFF states by trxG and PcG proteins. Genes Dev. 20, 2041-2054 (2006).
118. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745 (2007).
119. De Braekeleer, M., Morel, F., Le Bris, M. J., Herry, A. & Douet-Guilbert, N. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res. 25, 1931-1944 (2005).
120. Fair, K. et al. Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells. Mol. Cell Biol. 21, 3589-3597 (2001).
121. Cheung, N., Chan, L. C., Thompson, A., Cleary, M. L. & Eric So, C. W. Protein arginine-methyltransferasedependent oncogenesis. Nature Cell Biol. 23 September 2007 [Epub ahead of print].